Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1164)	6/28/2005 3:42:57 PM
From: Jibacoa	Read Replies (2) \| Respond to of 3722

DRRX Is trying to close above its June 17 H of 4.75 which will be another 52 wks.H DRRX Has a large Debt/Equt of 4.7 and the insiders that reportedly hold more than 20% of the stock have done some recent buying.<g>(In May from 3.05 to 3.45) The short ratio is around 25, so there could be some SS in the menu.<g> The loss in the 1st Q was $0.10/shr vs. $0.12/shr in 2004 and the EL for 2005 is around $0.44 vs, 0,55/shr in 2004 bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (1164)	7/21/2005 2:31:57 PM
From: Jibacoa	Respond to of 3722

CGTK Is trying again today to go over its July Hs and test its June 29 H at 2.93 <g> As previously mentioned, it announced last month that its NF-kappaB Decoy drug candidate was effective in reducing disease activity in Crohn's disease and ulcerative colitis. And today it announced that it started treating patients in its PI/II of its NF-kB Decoy for atopic dermatitis in Switzerland and Australia. The stock is up more than 5% today, but as previously mentioned,still far from closing its downgaps.<g>. bigcharts.marketwatch.com Bernard